Should I buy Healthpeak Properties (DOC) stock or is it too late?
⭐ The most reliable of them, either direction: Cantor Fitzgerald — 77% of its targets hit on this sector (13 calls tested). It aims for $23 (+8.4 %), call made on August 7, 2026, maturing on August 7, 2027 (21 d ago).
Firm-by-firm track record on Healthpeak Properties
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Scotiabank | 40 % | +0.9 % | 5 | $21 -1% |
| Mizuho | 20 % | -1.8 % | 5 | $24 +13% |
| Wedbush | 0 % | -12.3 % | 5 | $22 +4% |
| RBC Capital | 0 % | -19.6 % | 6 | $24 +13% |
✅ Reasons to believe
- Pays a dividend (5.7% yield) — regular income on top of potential upside.
⚠️ Reasons to hesitate
- Even the most reliable firm on DOC, JP Morgan (50% hit rate, 2 scored calls), only targets $21 (call made on June 24, 2026, maturing on June 24, 2027) (-1%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 12 ratings, 8 are neutral.
- Limited upside: the median target is only +6% from the current price.
- High valuation (P/E ~62): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on DOC
Median target $23 (+6%) · 12 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Healthpeak Properties now?
We won't decide for you. The facts: 33% of analysts rate it a buy, median target $23 (+6%), and JP Morgan (most reliable on DOC, 50%) targets $21. Weigh that against valuation (P/E ~62). This is not personalized advice.
Is it too late to invest in Healthpeak Properties?
Not according to analysts: the median target ($23) is still +6% above the current price ($21) (most reliable on DOC: JP Morgan, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Healthpeak Properties still worth investing in?
It depends on the gap between the price ($21) and its estimated value: analysts target $23 on median (+6%), with 33% buys (most reliable on DOC: JP Morgan, 50%). Cross-check with their real reliability on DOC and the cautions above. Information, not advice.
What's the main risk in buying DOC?
Even the most reliable firm on DOC, JP Morgan (50% hit rate, 2 scored calls), only targets $21 (call made on June 24, 2026, maturing on June 24, 2027) (-1%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Healthpeak Properties profile (consensus, analyst reliability, price target, performance).